Machine-type communications and large-scale information processing architectures are among key (r)evolutionary enhancements of emerging fifth-generation (5G) mobile cellular networks. Massive data acquisition and processing will make 5G network an ideal platform for large-scale system monitoring and control with applications in future smart infrastructures. In this work, we investigate a capability of such a 5G network architecture to provide the state estimate of an underlying linear system from the input obtained via large-scale deployment of measurement devices. Assuming that the measurements are communicated via densely deployed cloud radio access network (C-RAN), we formulate and solve the problem of estimating the system state from the set of signals collected at C-RAN base stations. Our solution, based on the Gaussian Belief-Propagation (GBP) framework, allows for large-scale and distributed deployment within the emerging 5G information processing architectures. The presented numerical study demonstrates the accuracy, convergence behavior and scalability of the proposed GBP-based solution to the large-scale state estimation problem.

Breast cancer risk is influenced by rare coding variants in susceptibility genes, such as BRCA1, and many common, mostly non-coding variants. However, much of the genetic contribution to breast cancer risk remains unknown. Here we report the results of a genome-wide association study of breast cancer in 122,977 cases and 105,974 controls of European ancestry and 14,068 cases and 13,104 controls of East Asian ancestry. We identified 65 new loci that are associated with overall breast cancer risk at P < 5 × 10−8. The majority of credible risk single-nucleotide polymorphisms in these loci fall in distal regulatory elements, and by integrating in silico data to predict target genes in breast cells at each locus, we demonstrate a strong overlap between candidate target genes and somatic driver genes in breast tumours. We also find that heritability of breast cancer due to all single-nucleotide polymorphisms in regulatory features was 2–5-fold enriched relative to the genome-wide average, with strong enrichment for particular transcription factor binding sites. These results provide further insight into genetic susceptibility to breast cancer and will improve the use of genetic risk scores for individualized screening and prevention.

LHCb experiment at CERN has recently reported a set of measurements on lepton flavour universality in $b \to s$ transitions showing a departure from the Standard Model predictions. I will review the main ideas recently put forward to make sense out of these intriguing hints. Focusing on the new physics explanation, I will discuss the correlated signals expected in other low- and high-energy observables, that could help clarify the mysterious anomalies.

The Tactile Internet presently constitutes a vision of an Internet over which, in addition to current communications modalities, a sense of touch can be transported. In that case, people would no longer need to be physically near the systems they operate, but could control them remotely. The main problem that needs to be solved to realize the Tactile Internet is summarized by the “1 ms challenge.” If the response time of a system is below 1 ms, the end-user will not be able to tell the difference between controlling a system locally or from another location. This paper offers a summary of the requirements for haptic communications, followed by an overview of challenges in realizing the Tactile Internet. In addition, possible solutions to these challenges are proposed and discussed. For example, the development of the fifth generation mobile communication networks will provide a good foundation upon which a Tactile Internet could be built. This paper also describes the design of a modular testbed needed for testing of a wide variety of haptic system applications.

Objectives Efficacy, safety and immunogenicity results from the phase III study of SB2, a biosimilar of reference infliximab (INF), were previously reported through 54 weeks. This transition period compared results in patients with rheumatoid arthritis (RA) who switched from INF to SB2 with those in patients who maintained treatment with INF or SB2. Methods Patients with moderate to severe RA despite methotrexate treatment were randomised (1:1) to receive SB2 or INF at weeks 0, 2 and 6 and every 8 weeks thereafter until week 46. At week 54, patients previously receiving INF were rerandomised (1:1) to switch to SB2 (INF/SB2 (n=94)) or to continue on INF (INF/INF (n=101)) up to week 70. Patients previously receiving SB2 continued on SB2 (SB2/SB2 (n=201)) up to week 70. Efficacy, safety and immunogenicity were assessed up to week 78. Results Efficacy was sustained and comparable across treatment groups. American College of Rheumatology (ACR) 20 responses between weeks 54 and 78 ranged from 63.5% to 72.3% with INF/SB2, 66.3%%–69.4% with INF/INF and 65.6%–68.3% with SB2/SB2. Treatment-emergent adverse events during this time occurred in 36.2%, 35.6% and 40.3%, respectively, and infusion-related reactions in 3.2%, 2.0% and 3.5%. Among patients who were negative for antidrug antibodies (ADA) up to week 54, newly developed ADAs were reported in 14.6%, 14.9% and 14.1% of the INF/SB2, INF/INF and SB2/SB2 groups, respectively. Conclusions The efficacy, safety and immunogenicity profiles remained comparable among the INF/SB2, INF/INF and SB2/SB2 groups up to week 78, with no treatment-emergent issues or clinically relevant immunogenicity after switching from INF to SB2. Trial registration number NCT01936181; EudraCT number: 2012-005733-37.